PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Endocrinology and Metabolism10.3803/enm.2021.102202136122-29Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor AgonistsHun Jee Choe, Young Min Chohttp://e-enm.org/upload/pdf/enm-2021-102.pdf, http://e-enm.org/journal/view.php?doi=10.3803/EnM.2021.102, http://e-enm.org/upload/pdf/enm-2021-102.pdf
European Journal of Pharmacology10.1016/j.ejphar.2004.08.02320045011-3225-234Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonistsQing Dallas-Yang, Xiaolan Shen, Mathias Strowski, Edward Brady, Richard Saperstein, Raymond E. Gibson, Deborah Szalkowski, Sajjad A. Qureshi, Mari Rios Candelore, Judith E. Fenyk-Melody, Emma R. Parmee, Bei B. Zhang, Guoqiang Jianghttps://api.elsevier.com/content/article/PII:S0014299904009355?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0014299904009355?httpAccept=text/plain
Appetite10.1016/j.appet.2011.05.226201157S29Glucagon-like peptide-1 receptor agonists suppress water intakeN.J. Mckay, S.E. Kanoski, M.R. Hayes, D. Danielshttps://api.elsevier.com/content/article/PII:S0195666311003837?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0195666311003837?httpAccept=text/plain
BMJ10.1136/bmj.i55192016i5519Glucagon-like peptide-1 receptor agonists and risk of breast cancerShari D Bolen, Nisa M Maruthurhttp://data.bmj.org/tdm/10.1136/bmj.i5519, https://syndication.highwire.org/content/doi/10.1136/bmj.i5519
Journal of the Endocrine Society10.1210/jendso/bvaa201202153Erratum to: Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DMhttp://academic.oup.com/jes/article-pdf/5/3/bvaa201/36400338/bvaa201.pdf, http://academic.oup.com/jes/article-pdf/5/3/bvaa201/36400338/bvaa201.pdf
Pancreatology10.1016/j.pan.2019.05.115201919S45-S46Risk of acute pancreatitis after glucagon-like peptide-1 receptor agonistsAdriana Gherbonhttps://api.elsevier.com/content/article/PII:S1424390319302182?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1424390319302182?httpAccept=text/plain
Progress in Medicinal Chemistry10.1016/b978-0-444-62652-3.00002-8201345-96Medicinal Chemistry of Glucagon-Like Peptide Receptor AgonistsLyn H. Jones, David A. Pricehttps://api.elsevier.com/content/article/PII:B9780444626523000028?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:B9780444626523000028?httpAccept=text/plain
Cardiovascular Research10.1093/cvr/cvy124201811410e70-e71Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCELSigne Sørensen Torekovhttp://academic.oup.com/cardiovascres/article-pdf/114/10/e70/25195498/cvy124.pdf
Handbook of Incretin-based Therapies in Type 2 Diabetes10.1007/978-3-319-08982-9_3201631-43Glucagon-like peptide-1 receptor agonistsBaptist Gallwitzhttp://link.springer.com/content/pdf/10.1007/978-3-319-08982-9_3
Journal of Diabetes Investigation10.1111/j.2040-1124.2012.00241.x201236490-491Glucagon-like peptide-1 receptor agonists and their effects on weight reductionShyi-Jang Shinhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.2040-1124.2012.00241.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.2040-1124.2012.00241.x/fullpdf